High-mobility group box 1 (HMGB1) in childhood: From bench to bedside
| Autor: | Antonio Lacquaniti, Teresa Arrigo, Vincenzo Salpietro, Valeria Chirico, Maria Pia Calabrò, Carmelo Salpietro, Caterina Munafò, Michele Buemi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Glycation End Products
Advanced Vasculitis Arthritis Glycation End Products chemical and pharmacologic phenomena Autoimmune disease Cancer Children High-mobility group box 1 (HMGB1) Neurological diseases Newborn Preterm born Sepsis Arthritis Rheumatoid Autoimmune Diseases Biomarkers Child Disease Progression HMGB1 Protein Humans Inflammatory Bowel Diseases Lupus Erythematosus Systemic Signal Transduction Systemic Vasculitis Toll-Like Receptor 2 Toll-Like Receptor 4 HMGB1 Pathogenesis Mediator Rheumatoid medicine Neuroinflammation Lupus erythematosus biology Lupus Erythematosus business.industry Systemic medicine.disease Pediatrics Perinatology and Child Health Immunology TLR4 biology.protein Advanced business Systemic vasculitis |
| Popis: | High-mobility group box protein 1 (HMGB1) is a nonhistone nuclear protein that has a dual function. Inside the cell, HMGB1 binds DNA, regulating transcription and determining chromosomal architecture. Outside the cell, HMGB1 activates the innate system and mediates a wide range of physiological and pathological responses. HMGB1 exerts these actions through differential engagement of multiple surface receptors, including Toll-like receptor (TLR)2, TLR4, and receptor for advanced glycation end products (RAGE). HMGB1 is implicated as a late mediator of sepsis and is also involved in inflammatory and autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus. Interestingly, HMGB1 was associated with tumor progression, becoming a potential therapeutic target, due to its involvement in the resistance to chemotherapy. Its implication on the pathogenesis of systemic vasculitis and inflammatory bowel diseases has also been evaluated. Moreover, it regulates neuroinflammation after traumatic brain injuries or cerebral infectious diseases. The aim of this review is to analyze these different roles of HMGB1, both in physiological and pathological conditions, discussing clinical and scientific implications in the field of pediatrics. Conclusion: HMGB1 plays a key role in several pediatric diseases, opening new scenarios for diagnostic biomarkers and therapeutic strategies development. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|